机构：[1]Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.临床科室耳鼻咽喉-头颈外科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[2]Beijing Laboratory of Allergic Diseases and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.研究所耳鼻咽喉科研究所首都医科大学附属北京同仁医院首都医科大学附属同仁医院[3]Department of Otolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.[4]Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, China.[5]Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China.临床科室变态反应科首都医科大学附属北京同仁医院首都医科大学附属同仁医院
Chronic rhinosinusitis with nasal polyps (CRSwNP) has a high recurrence rate after surgery despite the availability of medical treatments. Multiple clinical and biological factors have been associated with poor post-operative outcomes in patients with CRSwNP. However, these factors and their prognostic values have not yet been extensively summarized.This systematic review included 49 cohort studies exploring the prognostic factors for post-operative outcomes in CRSwNP. A total of 7802 subjects and 174 factors were included. All investigated factors were classified into three categories according to their predictive value and evidence quality, of which 26 factors were considered plausible for post-operative outcome prediction. Previous nasal surgery, ethmoid-to-maxillary (E/M) ratio, fractional exhaled nitric oxide, tissue eosinophil count or percentage, tissue neutrophil count, tissue IL-5, tissue eosinophil cationic protein, and CLC or IgE in nasal secretion provided more reliable information for prognosis in at least two studies.Exploring predictors through noninvasive or minimally invasive methods for specimen collection is recommended for future work. Models combining multiple factors must be established, as no single factor is effective for the whole population.
基金：
National Natural Science Foundation of China (81970850 and 82271139), CAMS Innovation Fund for Medical Sciences (CIFMS) (2019-I2M-5-022 and 2021-I2M-C&T-B-098), Program for Changjiang Scholars and Innovative Research Team (IRT13082), Beijing Municipal Science and Technology Project (Z181100001618002).
第一作者机构：[1]Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.[2]Beijing Laboratory of Allergic Diseases and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.
通讯作者：
通讯机构：[1]Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.[2]Beijing Laboratory of Allergic Diseases and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.[3]Department of Otolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.[4]Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, China.[5]Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China.[*1]Department of Otolaryngology, Eye & ENT Hospital, Fudan University, No. 83, Fenyang Road, Xuhui District, Shanghai, Xuhui 200031, P.R. China[*2]Department of Otolaryngology, Head, and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, No. 1, DongJiaoMinXiang, DongCheng District, Beijing 100730, P.R. China
推荐引用方式(GB/T 7714)：
Cai Shiru,Lou Hongfei,Zhang Luo.Prognostic factors for post-operative outcomes in chronic rhinosinusitis with nasal polyps: a systematic review[J].EXPERT REVIEW OF CLINICAL IMMUNOLOGY.2023,19(8):867-881.doi:10.1080/1744666X.2023.2218089.
APA：
Cai Shiru,Lou Hongfei&Zhang Luo.(2023).Prognostic factors for post-operative outcomes in chronic rhinosinusitis with nasal polyps: a systematic review.EXPERT REVIEW OF CLINICAL IMMUNOLOGY,19,(8)
MLA：
Cai Shiru,et al."Prognostic factors for post-operative outcomes in chronic rhinosinusitis with nasal polyps: a systematic review".EXPERT REVIEW OF CLINICAL IMMUNOLOGY 19..8(2023):867-881
：